Track topics on Twitter Track topics that are important to you
Cell-based therapy developer BlueRock Therapeutics said today it will receive $1 million from New York State for establishing a neuroscience R&D hub in New York City—a hub whose activity will include a new research collaboration with Memorial Sloan-Kettering Cancer Center (MSK), from which the company was spun out in 2016. Headquartered in Cambridge, MA, BlueRock is building out a 7800-square-foot space within the Alexandria Center for Life Science, the 728,000-square-foot Manhattan campus operated by Alexandria Real Estate Equities. The campus is located between Bellevue Hospital and NYU Medical Center. BlueRock said the location will help connect the company to top academic and medical institutions as well as major hospitals; scientific, clinical, and entrepreneurial talent; investment capital; and the city’s growing commercial life science industry. The R&D hub will be BlueRock’s third location, next to its Cambridge HQ and a research, development, and manufacturing hub within the ...NEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...